SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

S-8 POS - Stevanato Group S.p.A. (0001849853) (Filer)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

6-K - Stevanato Group S.p.A. (0001849853) (Filer)

-All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:00 a.m. (GMT), and the Citi 2024 Global Healthcare Conference in Miami on Tuesday, December 3, 2024 at 1:45 p.m. (ET). A live webcast of each event will be ava

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi

The platform provides a versatile pre-filled and pre-loaded on-body solution, suitable for highly viscous biological drugs Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule

Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges. This press release features multimedia. View the full

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the Morgan Stanley Healthcare Conference in New York on Friday, September 6, 2024 at 7:00 a.m. (ET), and at the Bank of America Global Healthcare Conference in London on Wednesday, September 18, 2024 at 2:10 p.m. (BST). A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays of the webcasts will be available for appr

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total revenue. For the second quarter, diluted earnings per share were €0.08 and adjusted diluted earnings per share were €0.09. Adjusted EBITDA margin for the second quarter was 20.8%. The Company is updating its fiscal year 2024 guidan

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regis

Cisterna's site is the first to implement premium solutions outside the Group's headquarters in Piombino Dese to meet the growing demand for biopharmaceuticals, such as GLP-1s in Europe. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530371429/en/External sight of the new Stevanato Group's plant in Cisterna di Latina, Italy. (Photo: Business Wire) Located just a few kilomet

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528385017/en/Franco Stevanato, Ch

Morgan Stanley analyst Drew Ranieri maintains Stevanato Gr (NYSE:STVN) with a Equal-Weight and lowers the price target from $26 to $22.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant. Located just a few kilometers from the Group's first historic plant in Latina, the new site covers an area of 65,000 square meters and employs around 200 people. The facility started commercial production in Q4 2023 and houses advanced production lines developed by Stevanato Group for the production of EZ-fill® pre-sterilized syringes with the aim of responding to the modern challenges of the European market, constantly growing in biopharma

Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Moro will remain on the Company's Board of Directors.

Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duolingo reported quarterly earnings of 57 cents per share which beat the analyst consensus estimate of 27 cents by 111.11%. Quarterly sales came in at $167.6 million which beat the analyst consensus estimate of $165.677 million and is a 44.91% increase from the same period last year, according to data from Benzinga Pro. Duolingo sees second-quarter revenues of between $175 million and $177.5 million, versus the $176.9 million estimate and full-year 2024 revenues of between $726.5 million and $735.5 million, versus the $728.23 million estimate. Du

Stevanato Gr (NYSE:STVN) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 25 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $256.31 million which beat the analyst consensus estimate of $254.14 million by 0.85 percent. This is a 0.34 percent increase over sales of $255.43 million the same period last year.

On Thursday, Stevanato Group S.p.A. (NYSE:STVN) reported the first quarter of 236.0 million euros, down 1% Y/Y, compared to the consensus of 237.17 million euros. Adjusted diluted earnings per share were 0.08 euros compared to the consensus of 0.11 euros. Adjusted EBITDA margin for the first quarter was 21.4%. Sales fell due to lower revenue attributable to glass vials in the Biopharmaceutical and Diagnostic Solutions Segment resulting from the ongoing destocking of excess vial inventories that customers accumulated during the pandemic and lower revenue from the Engineering Segment.  Revenue from high-value solutions increased to 37% of total revenue in the first quarter of 2024, co

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total revenue. For the second quarter, diluted earnings per share were €0.08 and adjusted diluted earnings per share were €0.09. Adjusted EBITDA margin for the second quarter was 20.8%. The Company is updating its fiscal year 2024 guidan

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regis

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registra

- Establishes 2024 Guidance- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023. Fourth Quarter and FY 2023 Highlights (compared with the same period last year) Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue. For the fourth quarter, diluted earnings per share were €0.17 and adjusted diluted earnings per share were €0.18. Adjusted EBITDA margin for the fourth quarter was 27%. F

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its websi

- Reiterates Full Year 2023 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023. Third Quarter 2023 Highlights (compared with the same period last year) Third quarter revenue increased 11% to €271.4 million. Revenue from high-value solutions increased to 32% of total revenue. Net profit increased 4% to €37.9 million, and diluted earnings per share were €0.14. Adjusted net profit increased 6% to €40.1 million, and adjusted diluted earnings per share were €0.15.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, October 31, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-r

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution proposed to shareholders at the Extraordinary General Meeting of Shareholders ("EGM") held virtually on October 4, 2023 was passed. Details of the resolution submitted to, and approved by, the EGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/shareholders-meetings. The Shareholders resolved to delegate to the Board of Directors of the Com

Exane BNP Paribas initiated coverage of Stevanato Group S.p.A. with a rating of Outperform

Jefferies downgraded Stevanato Group S.p.A. from Buy to Hold and set a new price target of $29.00 from $39.00 previously

Stephens initiated coverage of Stevanato Group S.p.A. with a rating of Overweight and set a new price target of $33.00

CJS Securities initiated coverage of Stevanato Group S.p.A. with a rating of Market Outperform

Morgan Stanley downgraded Stevanato Group S.p.A. from Overweight to Equal-Weight and set a new price target of $34.00

Morgan Stanley reiterated coverage of Stevanato Group with a rating of Overweight and set a new price target of $22.00 from $30.00 previously

B of A Securities reiterated coverage of Stevanato Group with a rating of Buy and set a new price target of $24.00 from $30.00 previously

Wells Fargo reiterated coverage of Stevanato Group with a rating of Overweight and set a new price target of $21.00 from $26.00 previously

Citigroup reiterated coverage of Stevanato Group with a rating of Buy and set a new price target of $23.00 from $27.00 previously

Morgan Stanley reiterated coverage of Stevanato Group with a rating of Overweight and set a new price target of $28.00 from $26.00 previously